Here’s a more hopeful statistic: There are more than 3.8 million breast cancer survivors in the U.S., and Alliance for Cancer Gene Therapy is committed to increasing that number through the advancement of cancer cell and gene therapy.
Since its founding in 2001, ACGT has issued multi-year grants to several cell and gene therapy scientists with proposals concentrated on breast cancer. They include:
- Douglas Mahoney, PhD, of the University of Calgary
- Michael Z. Zin, MD, PhD, of Stanford University
- Steve Thorne, PhD, of the University of Pittsburgh
- Clodagh C. O’Shea, PhD, of Salk Institute for Biological Studies
ACGT also prioritizes cell and gene therapy research and development that can translate across multiple cancer types. For example, the advancements made in lung cancer treatment could be used to advance how we treat breast cancer.
While the number of breast cancer survivors is inspiring, there is potential for many more in the years to come thanks to the efforts of ACGT and the generosity of our donors.
As we recognize Breast Cancer Awareness Month and show support to the hundreds of thousands of women battling this disease, we ask for your help in advancing cell and gene therapy for breast cancer. Please donate today so we can continue to fund bold science that hopefully leads to cures.
Early detection helps save lives!
According to the American Cancer Society, when breast cancer is detected early, and is in the localized stage, the 5-year relative survival rate is 99%. Early detection includes doing monthly breast self-exams and scheduling regular clinical breast exams and mammograms.
